Lead Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Age ranged between18 and 80 years.
•Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic and histologic criteria) in clinical remission (SCCAI = 0) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics.
•Patients affected by Crohn's Disease (diagnosed on the base of clinic, endoscopic and histologic criteria) ) in clinical remission (CDAI \< 150) from at least 3 months and in stable therapy (without therapeutic modifications in the three previous months) with 5-ASA, immunomodulators and/or biologics.
•Fecal calprotectin at baseline \> 150 μg/g.

•Patients affected by Ulcerative Colitis and Crohn's Disease respectively with a SCCAI ≥ 1 and a CDAI ≥150.
•Patients on steroid therapy.
•Patients in therapy wih warfarin or other anticoagulants.
•Known or supposed ipersensitivity to eicosapentaenoic acid/omega 3.
•Women in fertile age which refuse to use contracceptives specified in the study (oral contraception, IUD) and breastfeed women.
•Patients with severe clinical conditions which the investigator consider to controindicate patient partecipation at the study.
•Therapy modifications and/or assumption of sperimental therapies within three months before the study inclusion.
•Patients unable to follow protocol procedures and to sign the informate consent.

Related studies

NCT06979336 · Ulcerative Colitis

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

NCT07184931 · Crohn's Disease

NCT07593352 · IBD and Renal Involement, Chronic Kidney Disease, and more

NCT06100289 · Ulcerative Colitis, Crohn's Disease

Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases